RxDoctor Payments Data

Alph Emmanuel, MD

Surgery · Fairfield, CTNPI 1134416860

Payments from drug & device makers

What this record shows

This record is dominated by education: $28,020 of the $37,923 with a category attached, or 73.9%. Intuitive Surgical accounts for 88.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $18,515 and has fallen 50.6% since, to $9,155 in 2025. Among surgery clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,923in general payments, 2019–2025

Across 251 payments — averaging $151.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$34K
  • Medtronic$2K
  • Novo Nordisk$722
  • Currax Pharmaceuticals LLC$528
  • Conmed Corporation$336
  • Apollo Endosurgery US Inc$316
  • plus $885 from 8 others

What the payments were for

  • Speaking & faculty fees$3,0008%
  • Travel & lodging$2331%
  • Food & beverage$6,66918%
  • Education$28,02074%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,923 in reported general payments places this provider in the 90th percentile of 289 surgery providers in Connecticut.

See all surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$14,521
Medicare patients
20
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$24,682
Pantoprazole Sodium12$186
Ondansetron OdtOndansetron11$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$722$24,68222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 289 surgery providers in Connecticut.

Other surgery in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →